SKAP1 and malignant colon neoplasm: Our results, together with those of a previous study showing that SKAP1 deficiency in T lymphocytes enhanced their antitumor immunity by suppressing PD‐1 expression,[6] indicate that SKAP1 inhibition is a promising adjuvant approach for immune therapy in colon cancer, which warrants further investigation.